Draft Labeling for Atomoxetine HCL Solution

The Food and Drug Administration (FDA) has released draft labeling for Atomoxetine HCL Solution, identified by docket number FDA-2026-P-2639-0006. This draft guidance provides proposed revisions to the drug's labeling information, which is a critical component for manufacturers in ensuring accurate product information and for healthcare providers in prescribing and administering the medication.

Manufacturers of Atomoxetine HCL Solution should review the draft labeling and consider submitting comments to the FDA by the specified deadline. This action is necessary to ensure their final product labeling aligns with regulatory expectations and to potentially influence the final guidance. Failure to comply with final labeling requirements could result in regulatory action.